Results 201 to 210 of about 3,468,441 (283)

Model‐Informed Evaluation of Hydroxyurea Exposure During Lactation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Hydroxyurea is a cornerstone therapy for sickle cell anemia; however, evidence guiding its use during lactation remains limited. This study aimed to develop a population pharmacokinetic (PK) model to characterize hydroxyurea disposition in maternal plasma and breast milk, and to quantify infant exposure under clinically relevant breastfeeding scenarios.
Anhar Hosawi   +5 more
wiley   +1 more source

Clinical Significance of Acute Kidney Injury in Idiosyncratic Drug‐Induced Liver Injury: A Multicentric Propensity Scores Matched Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Clinical significance of acute kidney injury in idiosyncratic drug‐induced liver injury: a multicentric propensity scores matched study. Evidence about the role of acute kidney injury (AKI) in idiosyncratic drug‐induced liver injury (DILI) is still scarce.
José María Pinazo‐Bandera   +15 more
wiley   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit   +6 more
wiley   +1 more source

Designing Governance for ESG: Incentive and Oversight Complementarities in Corporate Sustainability Performance

open access: yesCorporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT This study investigates how internal governance design supports credible ESG performance by distinguishing between Incentive and Oversight Architectures. Using 13,993 firm‐year observations of US nonfinancial firms from 2018 to 2024, we estimate fixed effects and two‐step system GMM models.
Beyza Gürel   +2 more
wiley   +1 more source

CEO Overconfidence and Corporate Social Responsibility: A Micro‐CSR Perspective

open access: yesCorporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT Although research on micro‐level CSR has increasingly emphasized individual‐level antecedents, the role of CEO overconfidence has not been systematically integrated into the literature. To address this gap, a systematic literature review was undertaken of 62 studies on CEO overconfidence and CSR, revealing a mixed picture of positive, negative,
Jannis Kreinhop
wiley   +1 more source

Home - About - Disclaimer - Privacy